Corcept Therapeutics Shares Fall Nearly 20% After Appeals Court Clears Teva Generic
Corcept Therapeutics shares plunged 19.8% after the U.S. Court of Appeals upheld a ruling that Teva’s proposed generic Korlym doesn't infringe two of Corcept’s patents, clearing the path for early competition. The decision removes a key patent shield, heightening risk to flagship Korlym revenue and increasing earnings uncertainty.
1. Appeals Court Ruling Clears Teva Generic
The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey district court decision finding no infringement of two Korlym-related patents by Teva’s proposed generic mifepristone label, removing a major legal barrier. Corcept’s argument that Teva’s dosing label would induce patented regimens was rejected, with the court citing safety concerns and alternative therapies.
2. Increased Competition Risk for Korlym
With patent protection eroded, Teva can advance its Korlym generic once regulatory approvals are secured, triggering earlier-than-expected competition. This decision undermines Corcept’s flagship franchise, potentially accelerating revenue erosion and pressuring market share in Cushing’s syndrome treatment.
3. Stock Price and Technical Weakness
Corcept shares tumbled roughly 19.8% on the ruling and are trading 24.4% below their 20-day simple moving average and 52.9% below their 100-day SMA. The stock’s 57.6% decline over 12 months and new 52-week lows signal pronounced bearish sentiment among investors.
4. Financial Outlook and Pipeline Pressure
Ahead of its Feb. 24 earnings report—where consensus estimates call for $0.31 EPS on $254.7 million revenue—Corcept must demonstrate growth beyond Korlym. The ruling intensifies the need for successful pipeline launches and portfolio diversification to offset potential generic headwinds.